Dr. Varun Monga, Clinical Assistant Professor of Hematology, Oncology, and Blood & Marrow Transplantation, presented at the Connective Tissue Oncology Society meeting in Lisbon, Portugal, last month. His poster details the results of a Phase I clinical trial combining an oncolytic herpes virus with radiation therapy in patients with localized sarcomas. This neoadjuvant approach, is meant to increase tumor necrosis thereby reducing the chance of distant metastases post-surgery. The results of the 14-week study, as detailed on Dr. Monga’s poster, reveal that the drug, Talimogene laherparepvec, was safe and well-tolerated by the patients involved. Nearly half of the patients planned for the Phase II trials have already been enrolled. Congratulations to Dr. Monga and the 16 other named researchers and clinicians who contributed to this study.
Monga Research on Display

